US antitrust authorities in 2020 merger reviews increased scrutiny on high-tech industries, particularly in the technology and pharmaceutical sectors. Regulators focused more on nascent competition and killer acquisitions while bringing out new initiatives, such as a study of past mergers by digital platforms. But regulators also disagreed on the correct approach, with dissents at